<DOC>
	<DOCNO>NCT00692159</DOCNO>
	<brief_summary>This study perform evaluate safety tolerability TRC102 combination Alimta . In addition safety , study also evaluate pharmacokinetics tumor response .</brief_summary>
	<brief_title>Study TRC102 Combination With Pemetrexed Cancer Patients</brief_title>
	<detailed_description>This study perform evaluate safety tolerability TRC102 combination Alimta . In addition safety , study also evaluate pharmacokinetics tumor response .</detailed_description>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>The patient give informed consent The patient willing able abide protocol The patient cancer curative therapy unavailable standard therapy fail The patient least 18 year age The patient adequate ability perform activity daily live The patient recover significant toxicity previous therapy The patient adequate organ function assess laboratory test The patient prior treatment highdose chemotherapy require stem cell rescue The patient currently treatment another therapeutic clinical trial receive investigational drug within 4 week prior first dose study The patient prior surgery , radiation systemic therapy within 4 week start study The patient history CNS cancer The patient unstable medical condition include ( limited ) cardiac disease , HIV/AIDS , history stroke , hepatitis significant paricardial , pleural peritoneal effusion The patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>TRC102</keyword>
	<keyword>Methoxyamine HCL</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Alimta</keyword>
	<keyword>Tracon</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Cancer</keyword>
	<keyword>BER</keyword>
	<keyword>Base Excision Repair</keyword>
	<keyword>Small Molecule</keyword>
	<keyword>Anti-folate</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Neoplastic Processes</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Pathological Conditions , Signs Symptoms</keyword>
</DOC>